Meeting
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
Authors
Martin Kelly Nicholas
University of Illinois at Chicago, Chicago, IL
Martin Kelly Nicholas , Matthias Holdhoff , Richard A. Peterson , Oana Cristina Danciu , Theodore M. Tarasow , Paul J. Hergenrother , Arkadiusz Z. Dudek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT02355535
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS3164)
DOI
10.1200/JCO.2019.37.15_suppl.TPS3164
Abstract #
TPS3164
Poster Bd #
147a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.
First Author: Oana C. Danciu
Poster
2015 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies.
First Author: Oana C. Danciu
Poster
2019 ASCO Annual Meeting
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.
First Author: Jing Wu
Poster
2018 ASCO Annual Meeting
Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.
First Author: Stefania Maraka